vialroom

#tirzepatide 2026-05-24

Sunday18 messages7 participantstimes are UTC
Highlights from this day
  • declared_value — follow up im at 5 and thinking about 2.4, did anyone gain anything from that step 11:52
  • VialBot — Digest for the week of 2025-07-02 has been published. 11:55
  • step_one_sian — is there a reason to titrate slower than the four week schedule 12:44
  • declared_value — did anyone find the GI easier than semaglutide at an equivalent effect 13:35
  • VialBot — Inter-lab diff for lot E-2205: 96.8% vs 99%. Within expected range. 16:43
DV

follow up im at 5 and thinking about 2.4, did anyone gain anything from that step

1
VB

Digest for the week of 2025-07-02 has been published.

NP

coming back to this anyone tracked whether the GI difference held at the top doses

DV

did anyone find the GI easier than semaglutide at an equivalent effect

medutest-report-g-0641.pdf
3 pages · 393 KB · not retained in the public archive
SO

is the sweet spot argument about effect or about side effects

[edited]
ST

went back to semaglutide after 17 months because the cost difference mattered more than the GI

ST

the sweet spot thing is survivorship, the people it worked for stayed and said so, happy to be corrected

SURMOUNT is weight

checked the units twice

VB

Inter-lab diff for lot E-2205: 96.8% vs 99%. Within expected range.

SO

the trials titrated every four weeks to a target, most people here stop at whatever works